# NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

> **NCT06737250** · PHASE2 · RECRUITING · sponsor: **NOBO Medicine** · enrollment: 33 (estimated)

## Conditions studied

- Primary CNS Lymphoma (PCNSL)

## Interventions

- **DRUG:** R2P -> RP

## Key facts

- **NCT ID:** NCT06737250
- **Lead sponsor:** NOBO Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737250, "NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06737250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*